NCT04526886 2025-10-06
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Dartmouth-Hitchcock Medical Center
Phase NA Completed
Clinical Trials
9 trialsNCT04166604 2025-08-19
LONGBOARD
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT07071844 2025-07-17
BETWEEN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT01271582 2019-01-29
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Asan Medical Center
Phase 4 Unknown
NCT01619423 2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01523431 2017-03-30
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2/3 Completed
NCT02781155 2016-05-24
Limiting Chemotherapy Side Effects by Using Moxa
East and North Hertfordshire NHS Trust
Phase 1/2 Unknown
NCT01164215 2015-10-09
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed